Blockade of paclitaxel-induced thymidine phosphorylase expression can accelerate apoptosis in human prostate cancer cells

被引:11
作者
Kikuno, N
Moriyama-Gonda, N
Yoshino, T
Yoneda, T
Urakami, S
Terashima, M
Yoshida, M
Kishi, H
Shigeno, K
Shiina, H
Igawa, M
机构
[1] Shimane Univ, Sch Med, Dept Urol, Izumo, Shimane 6938501, Japan
[2] Shimane Univ, Sch Med, Dept Biochem & Mol Med, Izumo, Shimane 6938501, Japan
[3] Shimane Univ, Sch Med, Pathol Labs, Izumo, Shimane 6938501, Japan
关键词
D O I
10.1158/0008-5472.CAN-04-0996
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Recently, survival benefit by chemotherapy using paclitaxel (PTX) and the induction of thymidine phosphorylase (TP) by PTX have been reported in several solid tumors. On the other hand, TP confers antiapoptotic effect on tumor cells through inhibition of caspase-8 activation in vitro. On the basis of these previous observations, we hypothesized that (a) TP can be induced after PTX treatment in human prostate cancer (PC) and (h) blockade of PTX-induced TP expression can enhance the apoptotic processes in human PC cells. PTX was used to find TP expression in all eight hormone-refractory PC cases after chemotherapy; however, cleaved caspase-8 was not expressed after chemotherapy in the six hormone-refractory PC cases with strong TP expression. In PC cell lines (PC-3, DU 145, and LNCaP), TP expression after PTX treatment was clearly up-regulated in a dose-dependent manner. Cell viability of PC cell lines treated with PTX and TP antisense was significantly reduced in a time-dependent and dose-dependent manner compared with the PTX treatment alone. Likewise, apoptotic index of PC cells treated with PTX and TP antisense was significantly increased in comparison with PTX alone. After complete blockade of PTX-induced TP translation by TP antisense transfection, cleaved form of caspase-3 and poly(ADP-ribose) polymerase was increased, and this exaggeration of apoptosis also ran parallel with caspase-8 activation in a PTX dose-dependent manner. However, in PC cell lines treated with TP antisense alone, neither caspase-3 nor poly(ADPribose) polymerase was cleaved despite caspase-8 activation. These results indicate that PTX-induced TP up-regulation is associated with decreased caspase-8 activation. This study is the first report showing that blockade of PTX-induced TP expression could exaggerate the processing of apoptosis in PC cells treated with PTX. Our results provide preclinical evidence that TP could be a new molecular target for enhancing the potency of PTX-mediated apoptosis in PC cells.
引用
收藏
页码:7526 / 7532
页数:7
相关论文
共 19 条
  • [1] Inhibition of drug-induced Fas ligand transcription and apoptosis by Bcl-XL
    Biswas, RS
    Cha, HJ
    Hardwick, JM
    Srivastava, RK
    [J]. MOLECULAR AND CELLULAR BIOCHEMISTRY, 2001, 225 (1-2) : 7 - 20
  • [2] Blagosklonny MV, 1996, CANCER RES, V56, P1851
  • [3] BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
  • [4] Induction of thymidine phosphorylase by interferon and taxanes occurs only in human cancer cells with low thymidine phosphorylase activity
    Fukushima, M
    Okabe, H
    Takechi, T
    Ichikawa, W
    Hirayama, R
    [J]. CANCER LETTERS, 2002, 187 (1-2) : 103 - 110
  • [5] Caspase-8 activation independent of CD95/CD95-L interaction during paclitaxel-induced apoptosis in human colon cancer cells (HT29-D4)
    Gonçalves, A
    Braguer, D
    Carles, G
    André, N
    Prevôt, C
    Briand, C
    [J]. BIOCHEMICAL PHARMACOLOGY, 2000, 60 (11) : 1579 - 1584
  • [6] Novel approaches to treating the asymptomatic hormone-refractory prostate cancer patient
    Gulley, JL
    Dahut, WL
    [J]. UROLOGY, 2003, 62 (6B) : 147 - 154
  • [7] The biochemistry of apoptosis
    Hengartner, MO
    [J]. NATURE, 2000, 407 (6805) : 770 - 776
  • [8] IDENTIFICATION OF ANGIOGENIC ACTIVITY AND THE CLONING AND EXPRESSION OF PLATELET-DERIVED ENDOTHELIAL-CELL GROWTH-FACTOR
    ISHIKAWA, F
    MIYAZONO, K
    HELLMAN, U
    DREXLER, H
    WERNSTEDT, C
    HAGIWARA, K
    USUKI, K
    TAKAKU, F
    RISAU, W
    HELDIN, CH
    [J]. NATURE, 1989, 338 (6216) : 557 - 562
  • [9] Johnson KR, 1999, CLIN CANCER RES, V5, P2559
  • [10] Johnson KR, 1997, CLIN CANCER RES, V3, P1739